Preoperative taxane-based chemotherapy and celecoxib for carcinoma of the esophagus and gastroesophageal junction: Results of a phase 2 trial

Journal of Thoracic Oncology

Volumn 6, Issue 6, 2011, Pages 1121-1127

  Altorki, Nasser K ^a   Christos, Paul ^b   Port, Jeff L ^a   Lee, Paul C ^a   Mirza, Farooq ^a   Spinelli, Cathy ^a   Keresztes, Roger ^c   Beneck, Debra ^b   Paul, Subroto ^a   Stiles, Brendon M ^a   Zhang, Yuwei ^d   Schrump, David S ^d  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Celecoxib; COX 2; Esophageal cancer

Indexed keywords

CARBOPLATIN; CELECOXIB; CYCLOOXYGENASE 2; DEXAMETHASONE; DIPHENHYDRAMINE; FLUORODEOXYGLUCOSE F 18; HISTAMINE H2 RECEPTOR ANTAGONIST; PACLITAXEL;

ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DEATH; DEEP VEIN THROMBOSIS; DISEASE FREE SURVIVAL; DRUG EFFICACY; ENDOSCOPIC ECHOGRAPHY; ESOPHAGOGASTRODUODENOSCOPY; ESOPHAGUS CARCINOMA; ESOPHAGUS RECONSTRUCTION; ESOPHAGUS RESECTION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART ATRIUM FIBRILLATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOTENSION; IMMUNOHISTOCHEMISTRY; LOWER ESOPHAGUS SPHINCTER; LUNG EMBOLISM; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT; SYNCOPE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 79958155469     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31821529a9     Document Type: Article

References (52)

1. Stewart BW, Kleihues P. World Cancer Report, Lyon, France: IARC Press, 2008.
2. Posner MC, Minsky BD, Ilson DH. Cancer of the esophagus, Ch. 39, Section 2. In T Vincent, J Devita, TS Lawrence, et al. (Eds.), Devita, Hellman, & Rosenberg's Cancer: Principles and Practice of Oncology. Philadelphia, PA: Lippincott Williams & Wilkins, 2008, pp. 993-1043.
3. Bates BA, Detterbeck FC, Bernard SA, et al. Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma. J Clin Oncol 1996;14:156-163. (Pubitemid 26020008)
4. Bidoli P, Bajetta E, Stani SC, et al. Ten-year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagus. Cancer 2002;94:352-361. (Pubitemid 34081363)
5. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997;337:161-167. (Pubitemid 27306287)
6. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998;339:1979-1984. (Pubitemid 29024130)
7. Kelsen DP, Minsky B, Smith M, et al. Preoperative therapy for esophageal cancer: a randomized comparison of chemotherapy versus radiation therapy. J Clin Oncol 1990;8:1352-1361. (Pubitemid 20252307)
8. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002;359: 1727-1733.
9. Gebski V, Burmeister B, Smithers BM, et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007;8:226-234. (Pubitemid 46291702)
10. Law S, Fok M, Chow S, et al. Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg 1997;114:210-217.
11. Ancona E, Ruol A, Santi S, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer 2001;91:2165-2174. (Pubitemid 32476382)
12. Sharma S, Stolina M, Yang SC, et al. Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin Cancer Res 2003;9: 961-968. (Pubitemid 36323698)
13. Riedl K, Krysan K, Pold M, et al. Multifaceted roles of cyclooxygenase-2 in lung cancer. Drug Resist Updat 2004;7:169-184. (Pubitemid 39024518)
14. Reddy BS, Rao CV, Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 1996;56:4566-4569. (Pubitemid 26338047)
15. Kawamori T, Rao CV, Seibert K, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcino-genesis. Cancer Res 1998;58:409-412. (Pubitemid 28087398)
16. Harris RE, Alshafie GA, Abou-Issa H, et al. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 2000;60:2101-2103. (Pubitemid 30225166)
17. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-1311. (Pubitemid 30151999)
18. Alshafie GA, Abou-Issa HM, Seibert K, et al. Chemotherapeutic evaluation of celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncol Rep 2000;7:1377-1381.
19. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-1952. (Pubitemid 30419089)
20. Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 2003;4:431-436. (Pubitemid 38050040)
21. Zimmermann KC, Sarbia M, Weber AA, et al. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999;59:198-204. (Pubitemid 29062978)
22. Wilson KT, Fu S, Ramanujam KS, et al. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 1998;58:2929-2934. (Pubitemid 28335064)
23. Li Z, Shimada Y, Kawabe A, et al. Suppression of N- nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by JTE-522, a selective COX-2 inhibitor. Carcinogenesis 2001;22:547-551. (Pubitemid 32288653)
24. Sawaoka H, Kawano S, Tsuji S, et al. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol 1998;274:G1061-G1067.
25. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-809. (Pubitemid 26404280)
26. Sandler AB, Dubinett SM. COX-2 inhibition and lung cancer. Semin Oncol 2004;31:45-52. (Pubitemid 38879414)
27. Buskens CJ, Van Rees BP, Sivula A, et al. Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology 2002;122:1800-1807. (Pubitemid 34651424)
28. Takatori H, Natsugoe S, Okumura H, et al. Cyclooxygenase-2 expression is related to prognosis in patients with esophageal squamous cell carcinoma. Eur J Surg Oncol 2008;34:397-402. (Pubitemid 351381291)
29. Altorki N. COX-2: a target for prevention and treatment of esophageal cancer. J Surg Res 2004;117:114-120. (Pubitemid 38317216)
30. Altorki NK, Subbaramaiah K, Dannenberg AJ. COX-2 inhibition in upper aerodigestive tract tumors. Semin Oncol 2004;31:30-36.
31. Xi H, Baldus SE, Warnecke-Eberz U, et al. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer. Clin Cancer Res 2005;11:8341-8347. (Pubitemid 41746946)
32. Altorki NK, Port JL, Zhang F, et al. Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer. Clin Cancer Res 2005;11:4191-4197. (Pubitemid 40791585)
33. Subbaramaiah K, Hart JC, Norton L, et al. Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 AND p38 mitogen-activated protein kinase pathways. J Biol Chem 2000;275:14838-14845. (Pubitemid 30337196)
34. Huang WZ, Fu JH, Wang DK, et al. Overexpression of cyclooxygenase-2 is associated with chemoradiotherapy resistance and prognosis in esophageal squamous cell carcinoma patients. Dis Esophagus 2008;21: 679-684.
35. Schneider BJ, Kalemkerian GP, Kraut MJ, et al. Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy. J Thorac Oncol 2008;3: 1454-1459.
36. Mutter R, Lu B, Carbone DP, et al. A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer. Clin Cancer Res 2009;15:2158-2165.
37. Tuynman JB, Buskens CJ, Kemper K, et al. Neoadjuvant selective COX-2 inhibition down-regulates important oncogenic pathways in patients with esophageal adenocarcinoma. Ann Surg 2005;242:840-849, discussion 849-850.
38. Altorki NK, Keresztes RS, Port JL, et al. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol 2003;21:2645-2650. (Pubitemid 46606306)
39. Milas L, Kishi K, Hunter N, et al. Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. J Natl Cancer Inst 1999;91:1501-1504. (Pubitemid 29424556)
40. Hida T, Kozaki K, Muramatsu H, et al. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 2000;6:2006-2011. (Pubitemid 30305099)
41. Greene FL, Compton CC, Fritz AG, et al. AJCC Cancer Staging Atlas, 6th ed., New York, NY: Springer, 2006.
42. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-1080. (Pubitemid 40365348)
43. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10. (Pubitemid 19099520)
44. Kohne CH, De Greve J, Hartmann JT, et al. Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol 2008;19:920-926. (Pubitemid 351627308)
45. Maiello E, Giuliani F, Gebbia V, et al. FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). Ann Oncol 2006;17(Suppl 7):vii55-vii59. (Pubitemid 43985181)
46. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007;25:4779-4786. (Pubitemid 350086481)
47. Robey RW, To KK, Polgar O, et al. ABCG2: a perspective. Adv Drug Deliv Rev 2009;61:3-13.
48. Szczuraszek K, Materna V, Halon A, et al. Positive correlation between cyclooxygenase-2 and ABC-transporter expression in non-Hodgkin's lymphomas. Oncol Rep 2009;22:1315-1323.
49. An Y, Ongkeko WM. ABCG2: the key to chemoresistance in cancer stem cells? Expert Opin Drug Metab Toxicol 2009;5:1529-1542.
50. Huang D, Gao Q, Guo L, et al. Isolation and identification of cancer stem-like cells in esophageal carcinoma cell lines. Stem Cells Dev 2009;18:465-473.
51. Edelman MJ, Watson D, Wang X, et al. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy - Cancer and Leukemia Group B Trial 30203. J Clin Oncol 2008;26:848-855. (Pubitemid 351398075)
52. Altorki N, Kent M, Ferrara C, et al. Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann Surg 2002;236:177-183. (Pubitemid 34809536)